You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Dosage 1

Bexsero is available as a white opalescent liquid suspension for injection in a pre-filled syringe and comes as a 0.5 ml dose.

                                                                      Illustrations copyrights of GlaxoSmithKline
   

One dose (0.5 ml) contains:

Recombinant Neisseria meningitidis group B NHBA fusion protein 50 micrograms
Recombinant Neisseria meningitidis group B NadA protein 50 micrograms
Recombinant Neisseria meningitidis group B fHbp fusion protein 50 micrograms
Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4

   25 micrograms

Summary of vaccination schedule 1

Age at first dose

Primary Immunisation

Intervals between Primary Doses

Booster

Infants, 2 months to 5 monthsa

Three doses each of 0.5 ml

Not less than 1 month

Yes, one dose between 12 and 15 months of age with an interval of at least 6 months between the primary series and booster doseb, c

Infants, 3 months to 5 months

Two doses
each of 0.5 ml

Not less than 2 months

Infants, 6 months to 11 months

Two doses each of 0.5 ml

Not less than 2 months

Yes, one dose in the second year of life with an interval of at least 2 months between the primary series and booster dosec

Children, 12 months to 23 months

Two doses each of 0.5 ml

Not less than 2 months

Yes, one dose with an interval of 12 months to 23 months between the primary series and booster dosec

Children, 2 years to 10 years

Two doses each of 0.5 ml

Not less than 1 month

A booster dose should be considered in individuals at continued risk of exposure to meningococcal disease, based on official recommendations

Adolescents (from 11 years) and adults*

Two doses each of 0.5 ml

Not less than 1 month

A booster dose should be considered in individuals at continued risk of exposure to meningococcal disease, based on official recommendations

a The first dose should be given no earlier than 2 months of age. The safety and efficacy of Bexsero in infants less than 8 weeks of age has not yet been established. No data are available.

b In case of delay, the booster should not be given later than 24 months of age.

c See section 5.1. The need for, and timing of, further booster doses has not yet been determined.

d See section 5.1.

* There are no data in adults above 50 years of age.

Method of administration 1

The vaccine is given by deep intramuscular injection preferably in:  

  • the anterolateral aspect of the thigh in infants

 

  • the deltoid muscle region of the upper arm in older subjects
503153139
                                                           Illustrations copyrights of GlaxoSmithKline

  • Separate injection sites must be used if more than one vaccine is administered at the same time.
  • The vaccine must not be injected intravenously, subcutaneously or intradermally and must not be mixed with other vaccines in the same syringe.

As with many vaccines, healthcare professional should be aware that a temperature elevation may occur following vaccination of infants and children (less than 2 years of age). Prophylactic administration of antipyretics at the time and closely after vaccination can reduce the incidence and intensity of post-vaccination febrile reactions. Antipyretic medication should be initiated according to local guidelines in infants and children (less than 2 years of age).

Co-Administration 1

Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines:

  • Diphtheria, 
  • Tetanus, 
  • Acellular pertussis, 
  • Haemophilus influenzae type b,
  • Inactivated poliomyelitis, 
  • Hepatitis B, 
  • Heptavalent pneumococcal conjugate, 
  • Measles, 
  • Mumps, 
  • Rubella, 
  • Varicella
  • Meningococcal group C-CRM conjugate
  • Meningococcal group ACWY

References:

  1. Bexsero summary of product characteristics

Prescription Only Medicine.
Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health http://www.phs.moh.gov.cy/web/guest/drug-search

Trade marks are owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies or its licensor.